Nanodiagnostics

A new frontier for clinical laboratory medicine

Hassan M E Azzazy, Mai M H Mansour, Steven (Steve) Kazmierczak

Research output: Contribution to journalArticle

149 Citations (Scopus)

Abstract

Background: The use of nanotechnologies for diagnostic applications shows great promise to meet the rigorous demands of the clinical laboratory for sensitivity and cost-effectiveness. New nanodiagnostic tools include quantum dots (QDs), gold nanoparticles, and cantilevers. QDs, which are the most promising nanostractures for diagnostic applications, are semiconductor nanocrystals characterized by high photostability, single-wavelength excitation, and size-tunable emission. QDs and magnetic nanoparticles can be used for barcoding of specific analytes. Gold and magnetic nanoparticles are key components of the bio-barcode assay, which has been proposed as a future alternative to the PCR. Methods: We examined articles published over the past 10 years investigating the use of QDs, gold nanoparticles, cantilevers, and other nanotechnologies in promising diagnostic applications. Results: Several nanodiagnostic assays have been developed, including a QD-based assay capable of detecting biodnylated prostate-specific antigen (PSA) at 0.38 ng/L, a bio-barcode assay capable of detecting 30 amol/L PSA in a 10 μL sample, and another able to detect 50 molecules of the Alzheimer marker amyloid β-derived diffusible ligand in 10 μL of cerebrospinal fluid. Conclusions: Nanodiagnostics promise increased sensitivity, multiplexing capabilities, and reduced cost for many diagnostic applications as well as intracellular imaging. Further work is needed to fully optimize these diagnostic nanotechnologies for clinical laboratory setting and to address the potential health and environmental risks related to QDs.

Original languageEnglish (US)
Pages (from-to)1238-1246
Number of pages9
JournalClinical Chemistry
Volume52
Issue number7
DOIs
StatePublished - Jul 2006

Fingerprint

Clinical laboratories
Quantum Dots
Clinical Medicine
Semiconductor quantum dots
Medicine
Nanoparticles
Nanotechnology
Gold
Bioassay
Prostate-Specific Antigen
Assays
Cerebrospinal fluid
Plasma diagnostics
Cost effectiveness
Environmental Health
Multiplexing
Amyloid
Nanocrystals
Cost-Benefit Analysis
Cerebrospinal Fluid

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Nanodiagnostics : A new frontier for clinical laboratory medicine. / Azzazy, Hassan M E; Mansour, Mai M H; Kazmierczak, Steven (Steve).

In: Clinical Chemistry, Vol. 52, No. 7, 07.2006, p. 1238-1246.

Research output: Contribution to journalArticle

Azzazy, Hassan M E ; Mansour, Mai M H ; Kazmierczak, Steven (Steve). / Nanodiagnostics : A new frontier for clinical laboratory medicine. In: Clinical Chemistry. 2006 ; Vol. 52, No. 7. pp. 1238-1246.
@article{3c206ecee73647e78065e40e5e360f4b,
title = "Nanodiagnostics: A new frontier for clinical laboratory medicine",
abstract = "Background: The use of nanotechnologies for diagnostic applications shows great promise to meet the rigorous demands of the clinical laboratory for sensitivity and cost-effectiveness. New nanodiagnostic tools include quantum dots (QDs), gold nanoparticles, and cantilevers. QDs, which are the most promising nanostractures for diagnostic applications, are semiconductor nanocrystals characterized by high photostability, single-wavelength excitation, and size-tunable emission. QDs and magnetic nanoparticles can be used for barcoding of specific analytes. Gold and magnetic nanoparticles are key components of the bio-barcode assay, which has been proposed as a future alternative to the PCR. Methods: We examined articles published over the past 10 years investigating the use of QDs, gold nanoparticles, cantilevers, and other nanotechnologies in promising diagnostic applications. Results: Several nanodiagnostic assays have been developed, including a QD-based assay capable of detecting biodnylated prostate-specific antigen (PSA) at 0.38 ng/L, a bio-barcode assay capable of detecting 30 amol/L PSA in a 10 μL sample, and another able to detect 50 molecules of the Alzheimer marker amyloid β-derived diffusible ligand in 10 μL of cerebrospinal fluid. Conclusions: Nanodiagnostics promise increased sensitivity, multiplexing capabilities, and reduced cost for many diagnostic applications as well as intracellular imaging. Further work is needed to fully optimize these diagnostic nanotechnologies for clinical laboratory setting and to address the potential health and environmental risks related to QDs.",
author = "Azzazy, {Hassan M E} and Mansour, {Mai M H} and Kazmierczak, {Steven (Steve)}",
year = "2006",
month = "7",
doi = "10.1373/clinchem.2006.066654",
language = "English (US)",
volume = "52",
pages = "1238--1246",
journal = "Clinical Chemistry",
issn = "0009-9147",
publisher = "American Association for Clinical Chemistry Inc.",
number = "7",

}

TY - JOUR

T1 - Nanodiagnostics

T2 - A new frontier for clinical laboratory medicine

AU - Azzazy, Hassan M E

AU - Mansour, Mai M H

AU - Kazmierczak, Steven (Steve)

PY - 2006/7

Y1 - 2006/7

N2 - Background: The use of nanotechnologies for diagnostic applications shows great promise to meet the rigorous demands of the clinical laboratory for sensitivity and cost-effectiveness. New nanodiagnostic tools include quantum dots (QDs), gold nanoparticles, and cantilevers. QDs, which are the most promising nanostractures for diagnostic applications, are semiconductor nanocrystals characterized by high photostability, single-wavelength excitation, and size-tunable emission. QDs and magnetic nanoparticles can be used for barcoding of specific analytes. Gold and magnetic nanoparticles are key components of the bio-barcode assay, which has been proposed as a future alternative to the PCR. Methods: We examined articles published over the past 10 years investigating the use of QDs, gold nanoparticles, cantilevers, and other nanotechnologies in promising diagnostic applications. Results: Several nanodiagnostic assays have been developed, including a QD-based assay capable of detecting biodnylated prostate-specific antigen (PSA) at 0.38 ng/L, a bio-barcode assay capable of detecting 30 amol/L PSA in a 10 μL sample, and another able to detect 50 molecules of the Alzheimer marker amyloid β-derived diffusible ligand in 10 μL of cerebrospinal fluid. Conclusions: Nanodiagnostics promise increased sensitivity, multiplexing capabilities, and reduced cost for many diagnostic applications as well as intracellular imaging. Further work is needed to fully optimize these diagnostic nanotechnologies for clinical laboratory setting and to address the potential health and environmental risks related to QDs.

AB - Background: The use of nanotechnologies for diagnostic applications shows great promise to meet the rigorous demands of the clinical laboratory for sensitivity and cost-effectiveness. New nanodiagnostic tools include quantum dots (QDs), gold nanoparticles, and cantilevers. QDs, which are the most promising nanostractures for diagnostic applications, are semiconductor nanocrystals characterized by high photostability, single-wavelength excitation, and size-tunable emission. QDs and magnetic nanoparticles can be used for barcoding of specific analytes. Gold and magnetic nanoparticles are key components of the bio-barcode assay, which has been proposed as a future alternative to the PCR. Methods: We examined articles published over the past 10 years investigating the use of QDs, gold nanoparticles, cantilevers, and other nanotechnologies in promising diagnostic applications. Results: Several nanodiagnostic assays have been developed, including a QD-based assay capable of detecting biodnylated prostate-specific antigen (PSA) at 0.38 ng/L, a bio-barcode assay capable of detecting 30 amol/L PSA in a 10 μL sample, and another able to detect 50 molecules of the Alzheimer marker amyloid β-derived diffusible ligand in 10 μL of cerebrospinal fluid. Conclusions: Nanodiagnostics promise increased sensitivity, multiplexing capabilities, and reduced cost for many diagnostic applications as well as intracellular imaging. Further work is needed to fully optimize these diagnostic nanotechnologies for clinical laboratory setting and to address the potential health and environmental risks related to QDs.

UR - http://www.scopus.com/inward/record.url?scp=33745463535&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745463535&partnerID=8YFLogxK

U2 - 10.1373/clinchem.2006.066654

DO - 10.1373/clinchem.2006.066654

M3 - Article

VL - 52

SP - 1238

EP - 1246

JO - Clinical Chemistry

JF - Clinical Chemistry

SN - 0009-9147

IS - 7

ER -